Eli Lilly and Co (US.LLY)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.LLY · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 52.6% | ↑ |
| ROE | 23.7% | ↑ |
| Cash Conversion | 72.1% | ↑ |
| D/E Ratio | 1.39 | ↑ |
| Gross Margin | 81.9% | → |
US.LLY (Eli Lilly and Co) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY --------------------------- FCF Conversion 52.6% ↑ ROE 23.7% ↑ Cash Conversion 72.1% ↑ D/E Ratio 1.39 ↑ Gross Margin 81.9% →
Key Metrics
US.LLY (Eli Lilly and Co) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY---------------------------FCF Conversion 52.6% ↑ROE 23.7% ↑Cash Conversion 72.1% ↑D/E Ratio 1.39 ↑Gross Margin 81.9% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies